Author

D. L. Kerr

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

C. E. McCoach· 2 shared C. Gomez· 2 shared C. M. Blakely· 2 shared F. Haderk· 2 shared L. Cech· 2 shared S. Nanjo· 2 shared V. Olivas· 2 shared W. Wu· 2 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. E. McCoach

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

F. Haderk, C. Fernandez-Mendez, L. Cech, J. Yu, I. M. Meraz, V. Olivas, D. Barbosa Rabago, D. L. Kerr, C. Gomez, D. V. Allegakoen, J. Guan, K. N. Shah, K. A. Herrington, O. M. Gbenedio, S. Nanjo, , T. G. Bivona

This study identifies a FAK-YAP signaling axis that drives drug-tolerant persister cells and residual disease in lung cancer, showing that inhibiting this axis improves tumor response to targeted therapies.

bioRxiv · Oct 23, 2021Cancer Biology

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

D. R. Caswell, M. K. Mayekar, P. Gui, E. K. Law, N. I. Vokes, C. M. Ruiz, M. Dietzen, M. Angelova, C. Bailey, O. Pich, B. Bakker, W. Wu, T. J. Humpton, D. L. Kerr, W. Hill, , Argyr

This study shows that targeted cancer therapy induces APOBEC-mediated mutagenesis, promoting drug resistance by increasing genetic diversity through mechanisms involving NF-κB activation and reduced DNA repair.

bioRxiv · Dec 18, 2020Cancer Biology

E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms

M. K. Jolly, K. E. Ware, S. Xu, S. Gilja, S. Shetler, Y. Yang, X. Wang, G. Austin, D. Runyambo, A. J. Hish, S. Bartholf DeWitt, J. T. George, R. T. Kreulen, M.-K. Boss, A. L. Lazarides, , J. A. Somarelli

This study identifies E-cadherin's role in suppressing sarcoma growth through both signaling (inhibiting p-CREB and TBX2) and mechanical (enhancing cell-cell adhesion) mechanisms.

bioRxiv · Jan 10, 2019Cancer Biology